Research Reports Initiation on Drug Makers Stocks -- Depomed, Pernix Therapeutics, Orexigen Therapeutics, and United Therapeutics

Tuesday, April 25, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 25, 2017 /PRNewswire/ --

Today's research on is focused on the Drug Manufacturers

space, which is engaged in the development of prescription and over-the-counter products that are used to prevent or treat illnesses in humans or animals. Four equities have been lined up for review this morning, and they are: Depomed Inc. (NASDAQ: DEPO),
Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Orexigen Therapeutics Inc. (NASDAQ: OREX), and United Therapeutics Corp. (NASDAQ: UTHR). Learn more about these stocks by downloading their free report at:


On Monday, shares in Newark, California headquartered Depomed Inc. recorded a trading volume of 1.14 million shares, and ended the session 1.76% higher at $11.57. The stock is trading 21.65% below its 50-day moving average. Shares of the Company, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have a Relative Strength Index (RSI) of 30.53.

On March 29th, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $22 a share to $19 a share.

On April 04, 2017, Depomed announced that, in accordance with its stated plans and the terms of the secured debt facility with Deerfield and Pharmakon Advisors, L.P., the former prepaid $100 million of principal amount of its $475 million secured indebtedness. In addition, Depomed paid a prepayment fee of $4 million. Under the terms of the seven-year loan agreement, which matures in 2022, Depomed intends to refinance the remainder of the $375 million secured indebtedness in 2017. The free research report on DEPO is available at:

Pernix Therapeutics  

Morristown, New Jersey headquartered Pernix Therapeutics Holdings Inc.'s stock closed the day 4.58% higher at $3.88. A total volume of 701,621 shares was traded, which was above their three months average volume of 700,350 shares. The Company's shares have surged 45.86% in the previous three months and 100.00% since the start of this year. The stock is trading 12.30% and 67.31% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Pernix Therapeutics, which develops, manufactures, markets, and sells pharmaceutical products, have an RSI of 58.23.

On March 28th, 2017, Pernix Therapeutics announced financial results for the three and twelve months ended December 31st, 2016. For Q4 2016, GAAP net revenues were $30.1 million, net loss was $86.1 million, and adjusted EBITDA was $12.5 million. For the year ended December 31st, 2016, net revenues were $140.8 million, net loss was $169.6 million, and adjusted EBITDA was $15.0 million. The complimentary report on PTX can be downloaded at:

Orexigen Therapeutics  

Shares in La Jolla, California headquartered Orexigen Therapeutics Inc. recorded a trading volume of 250,087 shares. The stock ended yesterday's trading session 3.11% higher at $2.98. The Company's shares have advanced 71.26% on an YTD basis. The stock is trading below its 200-day moving average by 9.60%. Furthermore, shares of Orexigen Therapeutics, which focuses on the development of pharmaceutical products, have an RSI of 44.02.

On March 27th, 2017, Orexigen Therapeutics announced that its wholly-owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Bruno Farmaceutici S.p.A. (Bruno) have executed a distributorship agreement for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy. Under the terms of the agreement, Bruno will be responsible for all commercialization activity and expenses. Orexigen will supply Mysimba to Bruno for a negotiated transfer price and upfront milestone payments at signing and first commercial sale. Visit us today and download our complete research report on OREX for free at:

United Therapeutics  

Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock finished Monday's session 1.43% higher at $122.71. A total volume of 803,425 shares was traded, which was above their three months average volume of 612,660 shares. The Company's shares are trading below their 200-day moving average by 7.42%. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 32.32.

On March 30th, 2017, research firm UBS initiated a 'Sell' rating on the Company's stock, with a target price of $112 per share.

On April 19th, 2017, United Therapeutics announced that it will report its Q1 2017 financial results before the market opens on Wednesday, April 26th, 2017. The Company will also host a teleconference on the same day at 9:00 a.m. ET. This teleconference is being webcast and can be accessed via the Company's website. Get free access to your technical report on UTHR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store